Roth Capital Issues Pessimistic Estimate for CAPR Earnings

Capricor Therapeutics, Inc. (NASDAQ:CAPR) – Research analysts at Roth Capital decreased their Q3 2025 EPS estimates for shares of Capricor Therapeutics in a research note issued on Tuesday, August 12th. Roth Capital analyst B. Pachaiyappan now anticipates that the biotechnology company will post earnings per share of ($0.66) for the quarter, down from their prior estimate of ($0.44). Roth Capital currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Capricor Therapeutics’ current full-year earnings is ($1.21) per share. Roth Capital also issued estimates for Capricor Therapeutics’ Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($2.37) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at $1.40 EPS, Q4 2026 earnings at $3.01 EPS and FY2026 earnings at $3.47 EPS.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.09). Capricor Therapeutics had a negative return on equity of 62.71% and a negative net margin of 181.71%.

A number of other research firms have also recently weighed in on CAPR. Jones Trading dropped their price objective on shares of Capricor Therapeutics from $40.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday, June 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Oppenheimer dropped their price objective on shares of Capricor Therapeutics from $43.00 to $22.00 and set an “outperform” rating on the stock in a report on Monday, June 23rd. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of Capricor Therapeutics in a report on Friday, July 11th. One analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $22.56.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock opened at $7.96 on Thursday. The firm’s 50-day moving average is $9.17 and its 200-day moving average is $10.99. Capricor Therapeutics has a 1 year low of $3.84 and a 1 year high of $23.40. The company has a market cap of $363.91 million, a P/E ratio of -4.85 and a beta of 0.59.

Hedge Funds Weigh In On Capricor Therapeutics

Several large investors have recently bought and sold shares of the stock. Farallon Capital Management LLC acquired a new position in Capricor Therapeutics during the 4th quarter valued at about $31,056,000. Geode Capital Management LLC increased its stake in Capricor Therapeutics by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 963,080 shares of the biotechnology company’s stock valued at $9,565,000 after buying an additional 61,701 shares during the period. Woodline Partners LP increased its stake in Capricor Therapeutics by 15.8% during the 1st quarter. Woodline Partners LP now owns 729,318 shares of the biotechnology company’s stock valued at $6,921,000 after buying an additional 99,384 shares during the period. Altium Capital Management LLC increased its stake in Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock valued at $9,853,000 after buying an additional 429,000 shares during the period. Finally, Octagon Capital Advisors LP acquired a new position in shares of Capricor Therapeutics in the 1st quarter worth approximately $4,270,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.